Paper Details

  1. Home
  2. Paper Details

Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and Access to Abortion.

Author: BealMargaret W, Eagen-TorkkoMeghan K, SimmondsKatherine E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The US Food and Drug Administration (FDA) has updated the labeling and safety regulations for mifepristone, allowing midwives, advanced practice nurses, and physician assistants to prescribe it. The updated label also extends the eligibility for use from 49 to 70 days' gestation and reduces the number of required visits from 3 to 2. These changes reflect current research and may improve access to mifepristone for women in the United States.
Paper Details　
Original Abstract of the Article :
This article provides information on recent changes in the US Food and Drug Administration (FDA) labeling and safety regulations for mifepristone (Mifeprex). The revised label now permits midwives, advanced practice nurses, and physician assistants to order and prescribe mifepristone, eliminating th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jmwh.12636

データ提供：米国国立医学図書館（NLM）

Updated FDA Regulations for Mifepristone: Implications for Access to Abortion

This study discusses recent changes in the U.S. Food and Drug Administration (FDA) regulations for mifepristone, a medication used for medication abortion. The FDA has revised the labeling and safety regulations for mifepristone, expanding access to the medication and simplifying the process for obtaining it. The study highlights the implications of these changes for clinical practice and access to abortion care.

Expanded Access to Mifepristone: A Shift in Abortion Care

The updated FDA regulations have significantly broadened access to mifepristone, enabling more healthcare providers, including midwives, advanced practice nurses, and physician assistants, to prescribe the medication. The changes also extend eligibility for use to a later gestational age and reduce the number of required visits. These modifications aim to simplify the process of obtaining mifepristone and make abortion care more accessible.

Navigating the Desert of Access to Abortion Care: Finding Pathways to Choice

Imagine access to abortion care as a path through a vast desert. The updated FDA regulations, like a newly discovered oasis, provide a more accessible and navigable route for individuals seeking abortion care. The changes aim to break down barriers and ensure that more people have access to safe and legal abortion services.

Dr.Camel's Conclusion

This study highlights the significant impact of updated FDA regulations for mifepristone on access to abortion care. The changes aim to simplify the process, expand access, and ensure that more people have the choice and resources they need to make decisions about their reproductive health.

Date :
  1. Date Completed 2018-04-09
  2. Date Revised 2018-04-09
Further Info :

Pubmed ID

28632953

DOI: Digital Object Identifier

10.1111/jmwh.12636

Related Literature

Article Analysis
・Side Effects of mifepristone (korlym)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.